Genscript BiotechGNNSF 66 Median PS Value is $4.05 as of Jul. 04, 2026, which is 1025% above its 10-year median of 0.36. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.48 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 277 Biotechnology companies, Genscript Biotech ranks better than 72.2% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Genscript Biotech's Median PS Value or its related term are showing as below:
GNNSF'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36 Med: 0.36 Max: 0.4
Current: 0.4
During the past 12 years, the highest Price to Median PS Value of Genscript Biotech was 0.40. The lowest was 0.36. And the median was 0.36.
GNNSF's Price-to-Median-PS-Value is ranked better than 72.2% of 277
companies
in the Biotechnology industry
Industry Median: 0.66
vs GNNSF: 0.40
Genscript Biotech (OTCPK:GNNSF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Genscript Biotech's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.60
/
4.05
=
0.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech Median PS Value Related Terms
Genscript Biotech Median PS Value Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNNSF vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Genscript Biotech's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 9.2255.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.439.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (GNNSF) has a Median PS Value of $4.05 as of Jul. 04, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Genscript Biotech and its competitors. This is 1025% above median its historical median of 0.36. Over the past decade, Genscript Biotech's Median PS Value has ranged from 0.36 to 0.40. According to the industry distribution chart, Genscript Biotech ranks #77 out of 277 companies in the Biotechnology industry, placing it in the top 27.8%.
Is Genscript Biotech's Median PS Value too high?
Genscript Biotech's current Median PS Value of $4.05 is 1025% above median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 0.40. The Biotechnology industry median Median PS Value is 0.66. Genscript Biotech's value of $4.05 is 513.6% above this industry median. Based on the distribution chart, Genscript Biotech ranks #77 out of 277 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #77 out of 277 companies for Median PS Value. This puts Genscript Biotech in the upper half of its industry. The industry median Median PS Value is 0.66. Genscript Biotech's value of $4.05 is 513.6% above this benchmark. Historically, Genscript Biotech's own Median PS Value has ranged from 0.36 to 0.40 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 0.66, Genscript Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.66, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current Median PS Value of $4.05 is 513.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median Median PS Value is 0.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Median PS Value is $4.05, which is 1025% above median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.48, compared to a current price of $1.60 — trading 35.5% below its estimated fair value. The current Median PS Value is $4.05, which is 1025% above median its 10-year median of 0.36 and 513.6% above the Biotechnology industry median of 0.66. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Median PS Value is $4.05 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $1.60 is trading 35.5% below its estimated GF Value™ of $2.48.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for GNNSF:
Median PS Value: $4.05 (1025% above median its 10-year median of 0.36)
GF Value™: $2.48 vs. price of $1.60 (35.5% below fair value)
Industry Position: 513.6% above the Biotechnology median (#77 of 277)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score
Get the complete analysis for GNNSF
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
